Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 25
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Acurx Pharmaceuticals Inc
ACXP
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.14
-0.005
-0.44%
Ult. Agg.: Oct 23, 5:58 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Acurx Pharmaceuticals Financials
Acurx Pharmaceuticals (ACXP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per
Benzinga Newsdesk
What's Going On With Acurx Pharmaceuticals Stock Today?
Acurx Pharmaceuticals (NASDAQ:ACXP) shares down on Friday after reporting net loss for Q4 2025, but with positive cash and $1.5M raised.
Nabaparna Bhattacharya
Earnings Scheduled For March 13, 2026
Benzinga Insights
PRO
Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share
Benzinga Newsdesk
PRO
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share
Benzinga Newsdesk
Earnings Scheduled For November 12, 2025
Benzinga Insights
